KYMR

Kymera Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · kymeratx.com

$80.71

Mkt Cap $6.8B

52w Low $28.06 70.3% of range 52w High $103.00

50d MA $84.62 200d MA $66.84

P/E (TTM) -21.9x

EV/EBITDA -20.8x

P/B 4.3x

Debt/Equity 0.1x

ROE -19.7%

P/FCF -28.0x

RSI (14) —

ATR (14) —

Beta 2.29

50d MA $84.62

200d MA $66.84

Avg Volume 694.4K

About

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis supp…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Apr 30, 2026	BMO	-0.89	-0.71	+20.2%	81.51	+4.8%	-0.5%	-1.0%	—	—	—	—	—
Feb 26, 2026	BMO	-0.78	-0.97	-23.8%	90.68	-5.2%	+4.8%	+0.7%	-0.6%	-4.8%	-5.0%	-12.4%	—
Nov 4, 2025	BMO	-0.71	-0.90	-26.8%	59.72	-6.6%	+0.3%	+0.3%	+2.1%	-1.8%	+2.6%	+10.9%	—
Aug 11, 2025	BMO	-0.83	-0.95	-14.5%	40.62	-6.1%	-7.2%	-1.8%	+0.3%	+2.3%	+4.9%	+7.0%	—
May 9, 2025	BMO	-0.92	-0.82	+10.9%	30.77	+9.3%	-2.3%	+4.5%	+1.2%	-3.3%	-2.4%	+53.3%	—
Feb 27, 2025	BMO	-0.76	-0.88	-15.8%	35.36	-3.8%	-14.5%	-11.3%	-14.7%	-13.2%	-10.4%	-22.6%	—
Oct 31, 2024	BMO	-0.83	-0.82	+1.2%	47.67	-6.1%	-3.1%	-2.5%	-1.3%	+0.0%	+3.8%	+0.1%	—
Aug 7, 2024	BMO	-0.69	-0.58	+15.9%	41.42	+9.8%	-2.7%	+1.4%	+0.0%	+2.6%	+3.8%	+9.6%	—
May 2, 2024	BMO	-0.73	-0.69	+5.5%	36.24	-0.2%	+0.2%	+3.2%	+5.7%	+6.1%	+6.2%	-12.9%	—
Feb 22, 2024	BMO	-0.44	-0.25	+43.2%	38.67	+2.9%	+4.7%	+8.2%	+12.3%	+12.7%	+11.8%	+2.1%	—
Nov 2, 2023	BMO	-0.73	-0.90	-23.3%	11.55	-12.6%	+4.6%	+23.5%	+24.7%	+41.6%	+38.1%	+84.2%	—
Aug 3, 2023	BMO	-0.70	-0.67	+4.3%	21.50	+9.3%	+11.1%	+5.0%	-6.6%	-7.4%	-7.8%	-7.4%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 3	UBS	Maintains	Buy → Buy	—	$90.10	$87.41	-3.0%	-4.2%	-4.4%	-7.3%	-7.3%	-5.6%
Mar 2	Citigroup	Maintains	Buy → Buy	—	$91.35	$89.24	-2.3%	-1.4%	-5.5%	-5.7%	-8.6%	-8.6%
Mar 2	Stephens & Co.	Maintains	Overweight → Overweight	—	$91.35	$89.24	-2.3%	-1.4%	-5.5%	-5.7%	-8.6%	-8.6%
Feb 26	BTIG	Maintains	Buy → Buy	—	$90.68	$86.00	-5.2%	+4.8%	+0.7%	-0.6%	-4.8%	-5.0%
Feb 26	Piper Sandler	Maintains	Overweight → Overweight	—	$90.68	$86.00	-5.2%	+4.8%	+0.7%	-0.6%	-4.8%	-5.0%
Feb 3	BTIG	Maintains	Buy → Buy	—	$75.62	$75.16	-0.6%	+2.1%	+2.8%	+0.4%	+5.2%	+4.5%
Jan 28	Barclays	Maintains	Overweight → Overweight	—	$72.15	$72.54	+0.5%	-1.4%	+2.4%	+0.7%	+4.8%	+7.0%
Jan 15	BTIG	Maintains	Buy → Buy	—	$75.21	$75.37	+0.2%	-5.4%	-7.5%	-9.4%	-5.9%	-3.2%
Jan 6	Wolfe Research	Downgrade	Outperform → Peer Perform	—	$72.41	$70.66	-2.4%	+1.5%	+5.9%	+3.5%	+3.3%	+0.9%
Dec 22	B. Riley Securities	Maintains	Buy → Buy	—	$83.99	$84.73	+0.9%	+0.4%	-0.5%	-1.0%	-3.2%	-4.3%
Dec 16	RBC Capital	Maintains	Outperform → Outperform	—	$85.68	$86.32	+0.7%	-1.7%	-4.2%	-7.1%	-2.0%	-1.6%
Dec 11	Mizuho	Maintains	Outperform → Outperform	—	$89.89	$90.74	+0.9%	-2.3%	-0.2%	-4.7%	-6.3%	-8.7%
Dec 11	Stephens & Co.	Maintains	Overweight → Overweight	—	$89.89	$90.74	+0.9%	-2.3%	-0.2%	-4.7%	-6.3%	-8.7%
Dec 10	JP Morgan	Maintains	Overweight → Overweight	—	$86.88	$93.07	+7.1%	+3.5%	+1.1%	+3.2%	-1.4%	-3.1%
Dec 9	Barclays	Maintains	Overweight → Overweight	—	$94.30	$90.72	-3.8%	-7.9%	-4.7%	-6.9%	-4.9%	-9.1%
Dec 9	Wells Fargo	Maintains	Overweight → Overweight	—	$94.30	$90.72	-3.8%	-7.9%	-4.7%	-6.9%	-4.9%	-9.1%
Dec 9	BofA Securities	Maintains	Buy → Buy	—	$94.30	$90.72	-3.8%	-7.9%	-4.7%	-6.9%	-4.9%	-9.1%
Dec 9	BTIG	Maintains	Buy → Buy	—	$94.30	$90.72	-3.8%	-7.9%	-4.7%	-6.9%	-4.9%	-9.1%
Dec 9	Citigroup	Maintains	Buy → Buy	—	$94.30	$90.72	-3.8%	-7.9%	-4.7%	-6.9%	-4.9%	-9.1%
Dec 9	Truist	Maintains	Buy → Buy	—	$94.30	$90.72	-3.8%	-7.9%	-4.7%	-6.9%	-4.9%	-9.1%
Dec 9	Morgan Stanley	Maintains	Overweight → Overweight	—	$94.30	$90.72	-3.8%	-7.9%	-4.7%	-6.9%	-4.9%	-9.1%
Dec 9	Piper Sandler	Maintains	Overweight → Overweight	—	$94.30	$90.72	-3.8%	-7.9%	-4.7%	-6.9%	-4.9%	-9.1%
Dec 9	Oppenheimer	Maintains	Outperform → Outperform	—	$94.30	$90.72	-3.8%	-7.9%	-4.7%	-6.9%	-4.9%	-9.1%
Dec 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$94.30	$90.72	-3.8%	-7.9%	-4.7%	-6.9%	-4.9%	-9.1%
Dec 9	Jefferies	Maintains	Buy → Buy	—	$94.30	$90.72	-3.8%	-7.9%	-4.7%	-6.9%	-4.9%	-9.1%
Dec 9	Leerink Partners	Maintains	Outperform → Outperform	—	$94.30	$90.72	-3.8%	-7.9%	-4.7%	-6.9%	-4.9%	-9.1%
Nov 26	Truist	Maintains	Buy → Buy	—	$66.04	$66.89	+1.3%	+2.8%	+2.8%	+1.2%	-2.7%	-0.1%
Nov 5	Barclays	Maintains	Overweight → Overweight	—	$59.91	$59.07	-1.4%	-0.0%	+1.8%	-2.1%	+2.3%	+5.8%
Nov 5	Wells Fargo	Maintains	Overweight → Overweight	—	$59.91	$59.07	-1.4%	-0.0%	+1.8%	-2.1%	+2.3%	+5.8%
Nov 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$59.91	$59.07	-1.4%	-0.0%	+1.8%	-2.1%	+2.3%	+5.8%
Oct 22	BTIG	Maintains	Buy → Buy	—	$58.32	$59.19	+1.5%	-4.3%	-1.0%	+0.4%	+4.3%	+6.2%
Oct 17	Citigroup	Maintains	Buy → Buy	—	$60.46	$60.20	-0.4%	-1.0%	+0.1%	-3.5%	-7.7%	-4.5%
Oct 1	Oppenheimer	Maintains	Outperform → Outperform	—	$56.60	$56.30	-0.5%	-3.4%	-1.1%	+2.3%	+1.7%	+0.6%
Sep 30	Truist	Maintains	Buy → Buy	—	$58.50	$58.93	+0.7%	-3.2%	-6.6%	-4.3%	-1.0%	-1.6%
Sep 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$48.12	$49.39	+2.6%	+6.3%	+2.1%	+6.0%	+5.7%	+9.1%
Jun 27	Oppenheimer	Maintains	Outperform → Outperform	—	$45.71	$46.43	+1.6%	-3.5%	-4.5%	-2.8%	-2.6%	-2.0%
Jun 26	Wells Fargo	Maintains	Overweight → Overweight	—	$46.47	$45.51	-2.1%	-1.6%	-5.1%	-6.1%	-4.4%	-4.2%
Jun 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$46.47	$45.51	-2.1%	-1.6%	-5.1%	-6.1%	-4.4%	-4.2%
Jun 3	B. Riley Securities	Upgrade	Neutral → Buy	—	$43.13	$44.95	+4.2%	+1.0%	+2.6%	+10.5%	+10.4%	+9.3%
Jun 3	JP Morgan	Maintains	Overweight → Overweight	—	$43.13	$44.95	+4.2%	+1.0%	+2.6%	+10.5%	+10.4%	+9.3%
Jun 3	Morgan Stanley	Upgrade	Equal Weight → Overweight	—	$43.13	$44.95	+4.2%	+1.0%	+2.6%	+10.5%	+10.4%	+9.3%
May 13	UBS	Maintains	Buy → Buy	—	$32.17	$32.30	+0.4%	-3.2%	-7.5%	-6.7%	-6.0%	-6.1%
May 12	B. Riley Securities	Maintains	Neutral → Neutral	—	$30.07	$31.37	+4.3%	+7.0%	+3.6%	-1.1%	-0.2%	+0.6%
May 12	BofA Securities	Maintains	Neutral → Neutral	—	$30.07	$31.37	+4.3%	+7.0%	+3.6%	-1.1%	-0.2%	+0.6%
May 12	JP Morgan	Maintains	Overweight → Overweight	—	$30.07	$31.37	+4.3%	+7.0%	+3.6%	-1.1%	-0.2%	+0.6%
May 12	Guggenheim	Maintains	Buy → Buy	—	$30.07	$31.37	+4.3%	+7.0%	+3.6%	-1.1%	-0.2%	+0.6%
Feb 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$30.25	$30.20	-0.2%	+3.6%	-0.3%	+1.4%	+4.8%	+7.6%
Jan 21	Stephens & Co.	Maintains	Overweight → Overweight	—	$40.61	$41.65	+2.6%	+7.6%	+8.7%	+8.9%	+9.2%	+1.5%
Dec 27	Leerink Partners	Maintains	Outperform → Outperform	—	$42.02	$41.98	-0.1%	-4.5%	-6.4%	-4.3%	-2.7%	-1.0%
Dec 2	Wells Fargo	Upgrade	Equal Weight → Overweight	—	$46.85	$48.92	+4.4%	+1.9%	+0.1%	-1.8%	-5.9%	-0.4%

Recent Filings

8-K

Kymera Therapeutics, Inc. -- 8-K Filing

Kymera Therapeutics (KYMR) reported Q1 2026 results while advancing its oral degrader candidates KT-621 and KT-579 through clinical development, targeting multiple pipeline milestones this year.

Apr 30

8-K

Unknown — 8-K Filing

I cannot provide meaningful analysis from this filing excerpt, as it contains only standard signature blocks without substantive disclosure of what material event triggered the 8-K filing.

Mar 27

8-K

Kymera Therapeutics, Inc. -- 8-K Filing

Kymera Therapeutics appointed veteran biopharma executive Neil Graham as Chief Development Officer while advancing multiple clinical programs, including KT-621 in atopic dermatitis and asthma with data readouts expected through 2027.

Feb 26

8-K

Kymera Therapeutics, Inc. -- 8-K Filing

Kymera Therapeutics established an at-the-market equity offering agreement with TD Cowen, allowing the company to sell shares up to a specified amount with TD Cowen receiving up to 3.0% commission on proceeds.

Feb 26

Data updated apr 25, 2026 6:18pm · Source: massive.com